European Psychiatry - Volume 33 - March 2016

381 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S377
clinical implications and suggestions for future research directions
are considered.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
References
[1] Moallem N. SSP 2012.
[2] Barzman DH, et al. SSP 2006.
[3] Millan MJ. SSP 2000.
EV84
Is methylphenidate a prescription
drug being sold in the illegal market?
Analysis of samples submitted to a
drug checking facility
P. Quintana-Mathé , M. Grifell-Guàrdia ∗, Á. Palma ,
I. Fornís-Espinosa , C. Gil-Lladanosa , F. Caudevilla-Galligo ,
L. Galindo-Guarin , M. Farré-Albaladejo ,
M. Torrens-Melich , M. Ventura-Vilamala
1 Institut Català de la Salut, EAP Raval Sud, Barcelona, Spain
2 Associació Benestar i Desenvolupament, Energy Control, Barcelona,
Spain
3 Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions,
Barcelona, Spain
4 Hospital del Mar Medical Research Institute, Grup de Recerca en
Addiccions, Barcelona, Spain
5 ABD – Associació Benestar i Desenvolupament, Energy Control,
Barcelona, Spain
6 Universitat Autonoma de Barcelona, Bellaterra, Spain
7 Hospital Germans Trías i Pujol, Farmacologia Clínica, Badalona,
Spain
∗ Corresponding author.
Introduction Methylphenidate is a CNS stimulant approved for
treatment of ADHD. It is generally considered well tolerated
and exhibiting low dependence potential, although diversion for
recreational use has been described. Provided that its effects are
comparable to those of more popular drugs of abuse, such as
cocaine and amphetamines, we hypothesized that it could be sold
as such.
Objective The aim of this study was:
– to describe the presence of methylphenidate from the sam-
ples handled to, and analyzed by, Spanish harm-reduction service
energy control between August 2009 and August 2015;
– to determine whether it is being sold as other drugs.
Materials and methods All samples presented to energy control
(EC) were analyzed. EC is a Spanish harm-reduction non-
governmental organization that offers to users the possibility of
analyzing the substances they intend to consume.
Samples in which methylphenidate was detected using Gas
Chromatography–Mass Spectrometry were selected for this study.
Results From a total of 20062 samples, 17 contained
methylphenidate (0,09%), with no clear variations among the
years studied. The samples were mostly sold as amphetamine
(29%), methylphenidate (23%) and ethylphenidate (18%).
Conclusion Presence of Methylphenidate in the Spanish illegal
drug market seems anecdotic and stable over the studied time-
frame. Moreover, it was sold as substances with similar dosages,
lowering potential for life-threatening intoxications. Therefore, our
results suggest that diversion of methylphenidate into the drug
market as adulterant is not a concerning phenomenon.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV85
The role of buprenorphine
maintenance therapy in opioide
recidive prevention: Experiences from
Croatia
K. Radic ∗, D. Bosnjak , A. Korpar , A. Puljic , A. Bagaric
1 University Psychiatric Hospital Vrapˇce, Addictions Treatment
Department, Zagreb, Croatia
2 General Hospital Varaˇzdin, Department of Psychiatry, Varaˇzdin,
Croatia
∗ Corresponding author.
Introduction Buprenorphine, a partial agonist ofmu opioid recep-
tors and an antagonist at kappa opioid receptors, is widely used in
the treatment of the opioid addiction, as it reduces cravings and
effects of opioid withdrawal, decreases opioid consumption and
diminishes rewarding effects of it. In University Psychiatric Hospi-
tal Vrapˇce, the oldest psychiatric hospital in Croatia, buprenorphine
maintenance therapy is a standard and important part of integra-
tive psychiatric treatment offered to opioid drug users.
Aims To show potential benefits of buprenorphine maintenance
therapy as a pharmacological agent in psychiatric care for opioid
drug users.
Objectives To describe series of clinical cases in which the intro-
duction of buprenorphine in therapy of opioid drug users lead to
reduced number of their hospitalizations.
Methods Clinical cases from University Psychiatric Hospital
Vrapˇce Addictions Treatment Department were identified and the
course of patients’ treatment was analyzed. Summaries of cases,
with the emphasis on protective factors for stabile maintenance,
are presented.
Results After switching patients from various opiates to
buprenorphine in a controlled in-patient environment, our patients
becamemore functional and their integrative psychiatric treatment
could then start. After discharge, an improvement was visible in
different dimensions of their lives, and the re-admittance was the
exception, since recidives were rare. They continued their treat-
ment actively, in outpatient programmes of our clinic.
Conclusions Drug-seeking behaviour of presented opioid users
was avoided by buprenorphine maintenance therapy provided
with intermittent psychotherapeutic interventions or usual psy-
chiatric support in aftercare. In our experience, such integrative
psychiatric care prevents re-admittances and recidives.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV86
New drugs: Use of everyday
substances as substances of abuse
M.D.L.C. Ramirez Dominguez ∗, I. Prieto Sánchez , M. Nu˜nez Caro ,
L. Hernandez Gonzalez
Complejo Hospitalario de Huelva, Psiquiatria, Huelva, Spain
∗ Corresponding author.
Introduction Emerging drugs are a growing problem, of whichwe
have little information and clinical experience and pose a challenge
in everyday clinical practice because many are not detectable with
the test at our disposal and its effect on cognition and behavior are
not well known.
Methods Conduct a thorough literature review of all the material
in this regard has been published both in high impact journals and
in the last International Congress of Dual Pathology.
Results There are many and varied new substances used for
harmful/abuse consumption mainly for their sedative effects